Apellis Enterprise Value Over E B I T D A from 2010 to 2026
| APLS Stock | USD 20.16 0.54 2.61% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 45.4928192 | Current Value 43.22 | Quarterly Volatility 353.52550695 |
Check Apellis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 46.5 M or Selling General Administrative of 577.8 M, as well as many indicators such as Price To Sales Ratio of 3.0, Dividend Yield of 0.0 or PTB Ratio of 15.52. Apellis financial statements analysis is a perfect complement when working with Apellis Pharmaceuticals Valuation or Volatility modules.
Apellis | Enterprise Value Over E B I T D A | Build AI portfolio with Apellis Stock |
The evolution of Enterprise Value Over E B I T D A for Apellis Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Apellis Pharmaceuticals compares to historical norms and industry peers.
Latest Apellis Pharmaceuticals' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Apellis Pharmaceuticals over the last few years. It is Apellis Pharmaceuticals' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apellis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Apellis Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | 82.65 | |
| Coefficient Of Variation | 427.74 | |
| Mean Deviation | 161.09 | |
| Median | (11.66) | |
| Standard Deviation | 353.53 | |
| Sample Variance | 124,980 | |
| Range | 1.5K | |
| R-Value | (0.08) | |
| Mean Square Error | 132,547 | |
| R-Squared | 0.01 | |
| Significance | 0.77 | |
| Slope | (5.31) | |
| Total Sum of Squares | 2M |
Apellis Enterprise Value Over E B I T D A History
About Apellis Pharmaceuticals Financial Statements
Apellis Pharmaceuticals shareholders use historical fundamental indicators, such as Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Apellis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apellis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apellis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 45.49 | 43.22 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.